Jun. 23 at 3:13 PM
BofA, on June 10, from its Deep dive into
$RARE's OI Interim Analysis said, "If phase 3 is successful, KOLs envision broad usage" - says it sees high likelihood 2nd interim hits given supportive long-term ph 2 data.
$MREO
BofA additionally said, "Long-term ph 2 data showed pts with 14+ mos follow-up saw their AFR reduced 67%
from baseline. At 12-mos, patients saw a 22% mean increase in lumbar spine BMD (6-mos: 14%).
If the ph 3 replicates these results, our KOLs indicate that they would offer setrusumab to nearly all of their Ol patients including patients on bisphosphonates."
